Operational Highlights AprilOccupancy reached 73%, up 4% from last April, with one more roundtrip this year. Cabin nights increased by 18%. Average Cabin Revenue (ACR) increased by 1% compared to April 2025. Total ticket revenue increased by 19% compared to April last year. Operational onboard revenue grew by 14% compared to April last year.Booking Position 2026Solid position for 2026, with 68% of capacity booked – compared to 60% at the same time last year, around 8 percentage points (or 14% higher) ahead. Near-term booking patterns reflect seasonal group allotment cancellations, with recent geopolitical uncertainty potentially shifting some demand closer to departure. We target 10-15% ACR growth across cabin categories for 2026, supporting continued revenue growth and EBITDA margin expansion.Booking Position 202720% of 2027...

Daix (France), New York City (New York, United States), May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of two abstracts at the upcoming annual congress of the European Association for the Study of the Liver, EASL Congress 2026, to be held from May 27 to 30, 2026 in Barcelona. Details of the presentations are as follow:Abstract title: Lanifibranor-induced improvements in histological parameters and cardiometabolic markers in MASH are independent of weight change and closely associated with adiponectin inductionPublication number: FRI-189Type of presentation: Poster presentationAuthors: Mary...

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, will be presented in a poster presentation at the European Association for the Study of the Liver (EASL) Congress taking place May 27-30, 2026, in Barcelona, Spain. “We are pleased to present additional Phase 1a data on ABI-6250 at EASL,” said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. “As the only oral entry inhibitor currently in clinical development for chronic hepatitis D, ABI-6250 is designed to offer a differentiated approach, and these data further support our plan to advance directly into a Phase...

On 12 May 2026, Arco Vara AS completed the disposal of a 25% stake in the Bulgarian company Botanica Lozen EOOD to Kamaleo Invest OOD. Arco Vara AS published a stock exchange announcement regarding the transaction on 13 March 2026 in connection with entering into an agreement for the partial sale of its Bulgarian subsidiary (Arco Vara AS Signs Share Purchase Agreement for Partial Sale of Bulgarian Subsidiary). Simultaneously with the completion of the transaction, the parties entered into a shareholders’ agreement and a project management agreement, pursuant to which Kamaleo Invest OOD will manage the residential development project of Botanica Lozen EOOD. The local partner’s responsibilities include organising the activities necessary for the implementation of the project, including coordination of design and construction activities,...

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/. Details on the abstracts are as follows: Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection Abstract #: 588Title: Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis...

AB “Ignitis grupė” (hereinafter – the Group) publishes its Strategic Plan 2026–2029, which is attached to this notice. The Group continues to implement its ambitious strategy with the purpose to create a 100% secure and green energy ecosystem and to strengthen regional energy transition, which contributes to competitiveness and economic growth. We secure local, reliable energy to support household well-being, enhance business competitiveness and attract energy-intensive industries. Strategic plan overview Over the past three years, we have delivered strong strategic growth, nearly doubling Installed Green Capacities from 1.2 GW to 2.1 GW and increasing onshore wind and solar capacity 4.4 times to reach 1.0 GW. The Group is entering a new stage of energy transition, shifting from rapid capacity build-out to a value-over-volume approach. Over...

AB “Ignitis grupė” (hereinafter – the Group) publishes its Strategic Plan 2026–2029, which is attached to this notice. The Group continues to implement its ambitious strategy with the purpose to create a 100% secure and green energy ecosystem and to strengthen regional energy transition, which contributes to competitiveness and economic growth. We secure local, reliable energy to support household well-being, enhance business competitiveness and attract energy-intensive industries. Strategic plan overview Over the past three years, we have delivered strong strategic growth, nearly doubling Installed Green Capacities from 1.2 GW to 2.1 GW and increasing onshore wind and solar capacity 4.4 times to reach 1.0 GW. The Group is entering a new stage of energy transition, shifting from rapid capacity build-out to a value-over-volume approach. Over...

WUHAN, China, May 13, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, participated in the 2026 National Medical Industry Academic and Industry Integration Conference, held from May 6 to 9 in Wuhan. At the health management sub‑forum, Fangzhou presented its innovative “AI+Chronic Disease Service” solutions, addressing some of the most pressing challenges in chronic disease care. AI+H2H Ecosystem Underpins Full‑Cycle Chronic Disease Care In response to persistent challenges facing the healthcare industry, such as physicians’ time constraints, limited patient awareness of chronic disease risks, and poor medication adherence, Fangzhou emphasized the importance of integrated care that connects the hospital and the home. Drawing on a network...